These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 8381577

  • 1. Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
    Bailey TC, Powderly WG, Storch GA, Miller SB, Dunkel JD, Woodward RS, Spitznagel E, Hanto DW, Dunagan WC.
    Am J Kidney Dis; 1993 Feb; 21(2):196-201. PubMed ID: 8381577
    [Abstract] [Full Text] [Related]

  • 2. Sequential therapy--a prospective randomized trial of MALG versus OKT3 for prophylactic immunosuppression in cadaver renal allograft recipients.
    Frey DJ, Matas AJ, Gillingham KJ, Canafax D, Payne WD, Dunn DL, Sutherland DE, Najarian JS.
    Transplantation; 1992 Jul; 54(1):50-6. PubMed ID: 1631944
    [Abstract] [Full Text] [Related]

  • 3. A randomized prospective comparison of MALG with OKT3 for rescue therapy of acute myocardial rejection.
    Deeb GM, Bolling SF, Steimle CN, Dawe JE, McKay AL, Richardson AM.
    Transplantation; 1991 Jan; 51(1):180-3. PubMed ID: 1824803
    [Abstract] [Full Text] [Related]

  • 4. Prophylaxis of heart transplant rejection with either antithymocyte globulin-, Minnesota antilymphocyte globulin-, or an OKT3-based protocol.
    Ladowski JS, Dillon T, Schatzlein MH, Peterson AC, Deschner WP, Beatty L, Sullivan M, Scheeringa RH, Clark WR.
    J Cardiovasc Surg (Torino); 1993 Apr; 34(2):135-40. PubMed ID: 8320247
    [Abstract] [Full Text] [Related]

  • 5. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S, Alexander JW, Schroeder TJ, First MR.
    Clin Transplant; 1996 Apr; 10(2):186-90. PubMed ID: 8664516
    [Abstract] [Full Text] [Related]

  • 6. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3.
    Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, Schooley RT, Isaacson D, Doran M, Delvecchio A, Delmonico FL, Auchincloss H, Rubin RH.
    Transplantation; 1992 Jan; 53(1):68-72. PubMed ID: 1310173
    [Abstract] [Full Text] [Related]

  • 7. Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation. A plea for multicenter immunosuppressive trials.
    Ross DJ, Jordan SC, Nathan SD, Kass RM, Koerner SK.
    Chest; 1996 Apr; 109(4):870-3. PubMed ID: 8635362
    [Abstract] [Full Text] [Related]

  • 8. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.
    Luan FL, Samaniego M, Kommareddi M, Park JM, Ojo AO.
    Transpl Infect Dis; 2010 Dec; 12(6):473-9. PubMed ID: 20576019
    [Abstract] [Full Text] [Related]

  • 9. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center.
    Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA.
    Transplantation; 1993 Jul; 56(1):88-96. PubMed ID: 8333073
    [Abstract] [Full Text] [Related]

  • 10. Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin.
    Indudhara R, Novick AC, Hodge E, Goormastic M, Papajcik D, Mastroianni B, Cook D.
    Urology; 1996 Jun; 47(6):807-12. PubMed ID: 8677568
    [Abstract] [Full Text] [Related]

  • 11. CMV in kidney transplantation: a single center experience over 22 years.
    Nashan B, Lück R, Kliem V, Brunkhorst R, Schlitt HJ, Klempnauer J.
    Clin Transpl; 1999 Jun; ():181-8. PubMed ID: 11038636
    [Abstract] [Full Text] [Related]

  • 12. Antilymphocyte induction immunosuppression in the post-Minnesota anti-lymphocyte globulin era: incidence of renal dysfunction and delayed graft function. A single center experience.
    Malinow L, Walker J, Klassen D, Oldach D, Schweitzer E, Bartlett ST, Weir MR.
    Clin Transplant; 1996 Jun; 10(3):237-42. PubMed ID: 8826659
    [Abstract] [Full Text] [Related]

  • 13. Comparison of Minnesota antilymphoblast globulin and Upjohn antithymocyte globulin for induction immunosuppression of human renal allografts.
    Pescovitz MD, Book BK, Milgrom ML, Leapman SB, Petersen B, Filo RS.
    Surgery; 1994 Oct; 116(4):811-8. PubMed ID: 7940183
    [Abstract] [Full Text] [Related]

  • 14. OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation.
    Portela D, Patel R, Larson-Keller JJ, Ilstrup DM, Wiesner RH, Steers JL, Krom RA, Paya CV.
    J Infect Dis; 1995 Apr; 171(4):1014-8. PubMed ID: 7706779
    [Abstract] [Full Text] [Related]

  • 15. Failure of ganciclovir prophylaxis to completely eradicate CMV disease in renal transplant recipients treated with intense anti-rejection immunotherapy.
    Isenberg AL, Shen GK, Singh TP, Hahn A, Conti DJ.
    Clin Transplant; 2000 Jun; 14(3):193-8. PubMed ID: 10831076
    [Abstract] [Full Text] [Related]

  • 16. Induction immunosuppression with antilymphocyte globulin or OKT3 in cadaver kidney transplantation. Results of a single institution prospective randomized trial.
    Hanto DW, Jendrisak MD, So SK, McCullough CS, Rush TM, Michalski SM, Phelan D, Mohanakumar T.
    Transplantation; 1994 Feb; 57(3):377-84. PubMed ID: 8108873
    [Abstract] [Full Text] [Related]

  • 17. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
    Flechner SM, Avery RK, Fisher R, Mastroianni BA, Papajcik DA, O'Malley KJ, Goormastic M, Goldfarb DA, Modlin CS, Novick AC.
    Transplantation; 1998 Dec 27; 66(12):1682-8. PubMed ID: 9884259
    [Abstract] [Full Text] [Related]

  • 18. Clinical impact of replacing Minnesota antilymphocyte globulin with ATGAM.
    Lum CT, Umen AJ, Kasiske B, Goerdt P, Heim-Duthoy KL, Andersen RC, Odland MD, Ney AL, Jacobs DM, Rao KV.
    Transplantation; 1995 Feb 15; 59(3):371-6. PubMed ID: 7871567
    [Abstract] [Full Text] [Related]

  • 19. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T, Nampoory MR, Johny KV, Pacsa AS, Mini Abraham P, Nair MP, Abdel-Haleem M, Samhan M, Al-Mousawi M.
    Transplant Proc; 2004 Feb 15; 36(6):1847-9. PubMed ID: 15350495
    [Abstract] [Full Text] [Related]

  • 20. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO, Feitosa EB, Agena F, Pierrotti LC, Azevedo LSF, Kotton CN, David-Neto E.
    Transpl Infect Dis; 2018 Oct 15; 20(5):e12929. PubMed ID: 29809309
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.